AGP Picks
View all

AGP Executive Report

Last update: 2 hours ago

US–Liechtenstein Pharma Tariffs: The US Commerce Department says it will apply a 0% ad valorem tariff to certain specialty drugs and ingredients from India and 19 other jurisdictions, including Liechtenstein, as a 100% tariff on some patented pharma imports approaches on Sept 29. The carve-out covers medicines for rare diseases and other categories like infertility treatments, cell and gene therapies, antibody-drug conjugates, and animal pharmaceuticals—plus qualifying components. EU Rare Disease Treatment: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone) for male cerebral adrenoleukodystrophy (cALD) patients aged 2–12 with Gd-negative brain lesions, described as the first pharmacological option for early intervention in the EU. TB in Switzerland: Switzerland reported 544 tuberculosis infections in 2025 (including Liechtenstein), the highest since 2018, with the rise driven mainly by people of foreign origin. Health Funding Scandal (Malta): Malta’s Passports Fund halted €10m health-centre upgrades after procurement and compliance concerns, following findings tied to irregular refurbishment projects.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

fallback image
Sep. 7, 2026

Swiss parabolic flight campaign pivots toward commercial space applications

AGP

fallback image
Jul. 3, 2026

European Commission authorizes CinnaGen’s osteoporosis biosimilar Zandoriah in EU

AGP

fallback image
Jul. 28, 2026

The European releases its Summer 2026 edition

AGP

fallback image
Jul. 2, 2026

American Swiss Foundation honors Adrian Keller at leadership dinner in Rüschlikon

AGP


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Press Release Service Indeterminate
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Press Release Service
Indeterminate
India Among Countries Getting Zero US Tariffs on Select Specialty Pharma Products

India Among Countries Getting Zero US Tariffs on Select Specialty Pharma Products

Pharmaceutical Section 232 Tariffs: U.S. Department of Commerce Clarifies Specialty Drug Exemptions Before September 29 Deadline

Pharmaceutical Section 232 Tariffs: U.S. Department of Commerce Clarifies Specialty Drug Exemptions Before September 29 Deadline

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease


fallback image
Sep. 25, 2026

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

GlobeNewswire, Inc.

fallback image
Sep. 18, 2026

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

GlobeNewswire, Inc.

fallback image
Jul. 23, 2026

Healthcare Holding Switzerland Secures CHF 80 Million Syndicated Financing

GlobeNewswire, Inc.

fallback image
Jul. 24, 2026

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

GlobeNewswire, Inc.

fallback image
Jul. 1, 2026

SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma

GlobeNewswire, Inc.

fallback image
May 19, 2026

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

GlobeNewswire, Inc.

More press releases

Video Stories

YouTube video thumbnail: How Successful is Europe at Closing the Gender Gap Between Men and Women?
Play
How Successful is Europe at Closing the Gender Gap Between Men and Women?
YouTube video thumbnail: Europe Scrambles for Solutions as Russia Escalates Threats
Play
Europe Scrambles for Solutions as Russia Escalates Threats
Affinity Group Publishing Logo Showcase
Discover Affinity Group Publishing
YouTube video thumbnail: Police Block Drumcree Orange Order Parade in Portadown, Northern Ireland, After Protests
Play
Police Block Drumcree Orange Order Parade in Portadown, Northern Ireland, After Protests
YouTube video thumbnail:  5 Terror Arrests at Airbase Used by US Bombers - Possible Iran Link Investigated
Play
5 Terror Arrests at Airbase Used by US Bombers - Possible Iran Link Investigated

Video Title

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.